Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RCKTW | US
0.01
14.35%
Healthcare
Biotechnology
30/06/2024
18/10/2024
0.07
0.06
0.08
0.06
Rocket Pharmaceuticals Inc. together with its subsidiaries operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas Medioambientales y Tecnológicas Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company is headquartered in Cranbury New Jersey.
View LessPrice Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
235.1%1 month
251.9%3 months
256.3%6 months
295.0%-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.04
Range1M
0.10
Range3M
0.10
Rel. volume
0.46
Price X volume
556.71
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.91 | 0 | 3.70% | n/a | |
Viking Therapeutics Inc | VKTX | Biotechnology | 65.8 | 0 | 1.83% | n/a | |
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.2298 | 0 | 3.14% | n/a | |
VINC | VINC | Biotechnology | 0.38 | 0 | 0.66% | n/a | |
Vigil Neuroscience Inc. Common Stock | VIGL | Biotechnology | 3.96 | 0 | -0.75% | n/a | |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5.65 | 0 | 3.48% | n/a | |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 41.16 | 0 | 3.18% | n/a | |
Veracyte Inc | VCYT | Biotechnology | 34.44 | 0 | 0.38% | n/a | |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.53 | 0 | 0.40% | n/a | |
Vericel Corporation | VCEL | Biotechnology | 41.66 | 0 | 2.43% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.82 | 0 | 1.93% | n/a | |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.53 | - |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | - | 15.30 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 256.33 | 72.92 | Riskier |
Debt to Equity | - | -1.24 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | - | 3.78B | - |